Analyst Conference Summaries

Biotechnology Investor Aids

GlycoMimetics
GLYC

conference date: March 6, 2019 @ 5:30 AM Pacific Time

Biotech Bargain Basement: GlycoMimetics [January 8, 2019]

GlycoMimetics: Buy This Dip [April 4, 2018]

GlycoMimetics Remains Undervalued After Leukemia Data Release [June 14, 2017 at Seeking Alpha]

GlycoMimetics: Undercovered with Catalysts Coming [June 9, 2016 at Seeking Alpha]

Analyst Call Notes by William P. Meyers
2018
GlycoMimetics
Q4 2018
May 3, 2018
August 10, 2018
Nov. 2, 2018
March 6, 2019
2017
May 18, 2017
 
 Nov. 8, 2017
March 6, 2018
2016
05/04/2016
08/04/2016
11/04/2016
 03/01/2017
2015
tba
8/6/2015
11/12/2015 
2/29/2016

GlycoMimetics GMI-1271 Effective in Phase I Leukemia Trial [May 19, 2016]
GlycoMimetics Novel Therapeutic Approach [February 5, 2016 at Seeking Alpha]
I Buy GlycoMimetics [April 6, 2015 at Dissecting the Bull]
GlycoMimetics and Pfizer Initiate Phase 3 Rivipansel Trial [June 23, 2015]
FDA Grants Orphan Drug Status to GMI-1271 [May 14, 2015]

GlycoMimetics (GLYC) is a clinical-stage developer of glycobiology based therapies.

GlycoMimetics web site


 

Search

More Analyst Conference Notes:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INCY
 ISRG
 MCHP
 MYL
 PLX
 REGN
 SGEN
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN

 
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2019 William P. Meyers